Before the COVID-19 pandemic, the typical vaccine took more than five years to develop. Pfizer, Moderna and more than a half-dozen other biopharma companies raced from virus discovery to phase 3 testing of their COVID-19 vaccines in under a year, promising an end to the pandemic in 2021.

Now the industry is asking an important question: Can we take what we learned from COVID-19 vaccine successes and use it to speed up the development of other vaccines?

We’ll explore strategies for compressing timelines in vaccine R&D, preclinical research, clinical trials and manufacturing, with insight and advice from people who have been on the frontlines of COVID-19 vaccine development. And we’ll look at how these techniques are already enhancing vaccine development for a range of diseases, including HIV, respiratory syncytial virus and pneumonia.

Topics include:

  • Forming partnerships with the government, contract research organizations and others without the red tape that can slow down development.
  • Best practices for assessing long-term safety on a compressed timeline, including using preclinical testing to model safety, and designing post-marketing studies to track long-term results in human trial participants.
  • Setting up a manufacturing and distribution infrastructure early in the development process and engaging regulators in that process to ensure a smooth transition from clinical testing to commercialization.

Featured Speaker

Tadas Trunca

Sr. Manager, Product Management
Thermo Fisher Scientific

As a Senior Manager of Product Management at Thermo Fisher Scientific, he leads Nucleic Acid Therapeutics TheraPureTM raw materials product portfolio from development to commercial scale supply stages. His global Product Management group in particular focuses on enabling mRNA platform developers and commercializers by supplying starting and ancillary Nucleic Acid synthesis raw materials (enzymes, nucleotides, modified nucleotides products, Cap analogs). For the past 6 years at Thermo Fisher Scientific, Tadas played key role in enabling and partnering with multiple mRNA therapy developers by positioning Thermo Fisher Scientific as key strategic supplier and partner. He obtained his BSc in Biology from Vilnius University as well as Master of Business Administration from ISM University of Management and Economics.

Date:  Tuesday, June 8, 2021
Time:  1pm ET / 10am PT
Duration:  1 Hour

Register now for this webinar